Published in Pharmacol Res on September 09, 2006
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
Signals to promote myelin formation and repair. Nat Rev Neurol (2010) 1.95
Molecular mechanisms of inherited demyelinating neuropathies. Glia (2008) 1.68
Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes (Basel) (2014) 1.56
Pharmacological induction of the heat shock response improves myelination in a neuropathic model. Neurobiol Dis (2008) 1.00
Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease. Neurobiol Dis (2009) 0.97
P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy. J Biol Chem (2009) 0.93
Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets (2010) 0.92
Inherited neuropathies. Semin Neurol (2012) 0.89
Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life. Neurol Sci (2009) 0.84
Reliability of instrumented movement analysis as outcome measure in Charcot-Marie-Tooth disease: results from a multitask locomotor protocol. Gait Posture (2011) 0.82
Experimental therapeutics in hereditary neuropathies: the past, the present, and the future. Neurotherapeutics (2008) 0.76
Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions. Biol Open (2016) 0.76
Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis. Mult Scler Relat Disord (2016) 0.75
Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet (2004) 7.45
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol (2005) 2.32
Predictors of recovery of responsiveness in prolonged anoxic vegetative state. Neurology (2013) 2.26
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord (2010) 2.14
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain (2003) 2.11
Further evidence that SPG3A gene mutations cause autosomal dominant hereditary spastic paraplegia. Ann Neurol (2002) 2.07
Clinical-neurophysiological correlations in a series of patients with IgM-related neuropathy. Clin Neurophysiol (2013) 2.03
Nerve ultrasound findings in two cases of spinal accessory nerve palsy. Muscle Nerve (2014) 2.00
Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet (2003) 1.99
Sudden stopping in patients with cerebellar ataxia. Cerebellum (2013) 1.97
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol (2012) 1.95
Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet (2012) 1.88
Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet (2003) 1.72
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol (2009) 1.68
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain (2012) 1.67
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord (2013) 1.62
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci (2007) 1.61
Ultrasound as the first choice for peripheral nerve imaging? Neurology (2013) 1.57
Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord (2011) 1.56
Ross syndrome: a rare or a misknown disorder of thermoregulation? A skin innervation study on 12 subjects. Brain (2006) 1.55
UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol (2004) 1.54
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial. J Neurol Neurosurg Psychiatry (2011) 1.51
Induction of adipose differentiation related protein and neutral lipid droplet accumulation in keratinocytes by skin irritants. J Invest Dermatol (2003) 1.48
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord (2008) 1.48
Phenotypic characterization of hypomyelination and congenital cataract. Ann Neurol (2007) 1.46
Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. Parkinsonism Relat Disord (2008) 1.45
Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol (2003) 1.44
Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. Int J Cardiol (2013) 1.43
Case of acute motor conduction block neuropathy (AMCBN). Muscle Nerve (2009) 1.43
Blocking out the real diagnosis. Lancet (2011) 1.43
Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve (2002) 1.43
Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain (2008) 1.43
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain (2005) 1.42
Monoamine oxidase-a genetic variations influence brain activity associated with inhibitory control: new insight into the neural correlates of impulsivity. Biol Psychiatry (2005) 1.41
Study of multimodal evoked potentials in patients with type 1 Gaucher's disease. J Child Neurol (2005) 1.40
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
A dynamic ultrasonographic evaluation of the palmaris anomalous muscle. Clin Anat (2010) 1.40
Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol (2006) 1.39
Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol (2010) 1.39
Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol (2003) 1.39
Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci U S A (2005) 1.32
Myelinated nerve endings in human skin. Muscle Nerve (2007) 1.30
DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann Neurol (2005) 1.29
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord (2011) 1.27
Skin sympathetic adrenergic innervation: an immunofluorescence confocal study. Ann Neurol (2006) 1.26
Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol (2006) 1.24
Mitochondrial decay in the aging rat heart: evidence for improvement by dietary supplementation with acetyl-L-carnitine and/or lipoic acid. Ann N Y Acad Sci (2002) 1.24
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov Disord (2011) 1.23
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21
Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid. FASEB J (2002) 1.19
Participation in medical decision-making: attitudes of Italians with multiple sclerosis. J Neurol Sci (2008) 1.19
Carpal tunnel syndrome modifies sensory hand cortical somatotopy: a MEG study. Hum Brain Mapp (2002) 1.19
VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J (2007) 1.18
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology (2012) 1.17
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst (2006) 1.15
Polyunsaturated fatty acids as antioxidants. Pharmacol Res (2008) 1.15
A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle Nerve (2010) 1.15
Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol (2004) 1.14
Treatment for ulnar neuropathy at the elbow. Cochrane Database Syst Rev (2012) 1.14
Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med (2009) 1.13
The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol (2005) 1.13
C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol Aging (2012) 1.13
Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis (2006) 1.13
Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer (2008) 1.13
Usefulness of a morning routine EEG recording in patients with juvenile myoclonic epilepsy. Epilepsy Res (2007) 1.12
Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. Br J Nutr (2005) 1.11
Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord (2011) 1.11
Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci (2010) 1.11
Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract. Nat Genet (2006) 1.11
Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology (2006) 1.10
Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat (2013) 1.10
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol (2004) 1.10
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One (2013) 1.09
Comment on: "Ulnar Tunnel Syndrome with Ultrasonographic Nerve Imaging". Pain Physician (2015) 1.08
Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Mov Disord (2008) 1.08
Which is the goal of cognitive rehabilitation in multiple sclerosis: the improvement of cognitive performance or the perception of cognitive deficits? Mult Scler (2013) 1.07
Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling. J Med Genet (2012) 1.07
Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve (2004) 1.07
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet (2008) 1.06
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol (2005) 1.06
Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy. J Inherit Metab Dis (2011) 1.05